TIPS Plus Transvenous Obliteration for Gastric Varices

Cirrhosis, Liver Clinical Trial

Official title:

Single Center Prospective Pilot Study of Combined Transjugular Intrahepatic Portosystemic Shunt Creation Plus Transvenous Obliteration for the Treatment of Gastric Varices

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04044248
• Other study ID #: 2019-0156
• Status: Recruiting
• Start date: April 4, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2024
• Source: University of Illinois at Chicago
• Contact: Ron C Gaba, M.D. M.S.
• Phone: 312-996-0242
• Email: rgaba[@]uic.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Variceal hemorrhage (VH) from gastric varices (GVs) results in significant morbidity and mortality among patients with liver cirrhosis. In cases of acute bleeding, refractory bleeding, or high risk GVs, the transjugular intrahepatic portosystemic shunt (TIPS) creation and transvenous variceal obliteration procedures have used to treat GVs. While these techniques are effective, each is associated with limitations, including non-trivial rebleeding and hepatic encephalopathy rates for TIPS and aggravation of esophageal varices, development of new or worsening ascites, and formation of difficult to treat ectopic varices for transvenous obliteration. Increasingly, however, TIPS and transvenous obliteration are viewed as complimentary procedures that can be combined to reduce bleeding risk and ameliorate sequelae of portal hypertension. Yet, despite a strong mechanistic basis for their combination, there are few studies investigating the combined effectiveness of TIPS plus transvenous obliteration. Thus, the aim of this single center prospective pilot study is to assess the effectiveness and safety of combined TIPS creation plus transvenous obliteration for the treatment of GVs, with the overall goal of improving the clinical outcomes of patients with VH related to GVs. The work proposed could lead to important advances in the treatment of bleeding complications due to liver cirrhosis.

Description:

Liver cirrhosis-or scarring of the liver-occurs with a worldwide prevalence approximating 4.5-9.5%, affecting hundreds of millions of people. Cirrhosis results in 2% of all global mortality, approximating 1 million deaths per year, and affects more than 600,000 persons in the United States. Variceal hemorrhage (VH) from gastroesophageal varices (GEVs) is a leading cause of mortality in patients with liver cirrhosis. Gastric varices (GVs) occur in 5-33% of patients with cirrhotic liver disease and have a bleeding incidence of 25% within 2-years of development, 36% within 3-years, and 44% within 5-years. GVs are associated with high mortality rates approximating 25% at 2-years. First-line therapy in patients who have not bled includes preventative pharmaceuticals, while acute bleeding is typically treated with vasoconstrictive agents and endoscopic variceal ligation or sclerotherapy. In cases of acute hemorrhage, refractory bleeding, or high risk GVs, Interventional Radiology (IR) guided transjugular intrahepatic portosystemic shunt (TIPS) creation is recommended to decompress varices and divert blood flow through a controlled synthetic conduit. In the modern era, TIPS is associated with initial GV bleeding control in greater than 90% of cases. However, GV rebleeding rates after TIPS are non-trivial, widely ranging between 13-53%. Moreover, GVs are widely thought to remain patent and sustain bleeding at low portosystemic pressure gradients (PSGs), as is the case after TIPS. In addition, TIPS can also contribute to high rates hepatic encephalopathy (HE) due to increased portosystemic shunting. Recently, transvenous obliteration techniques-including balloon-occluded retrograde (BRTO) and antegrade (BATO) transvenous obliteration as well as more recent adaptations including coil- (CARTO) and plug-assisted (PARTO) retrograde transvenous obliteration-have been developed with the intent of directly eradicating GVs. While obliteration techniques are associated with high technical success rates approximating 91-100% and low rebleeding incidence less than 5%, the worsened portal hypertension that follows from GV closure results in adverse side effects, including aggravation of esophageal varices (EVs) in 33% of patients, development of new or worsening of ascites in 10% of patients, and formation of difficult to treat ectopic varices.

Traditionally, TIPS and transvenous obliteration have evolved in relative isolation as different philosophical strategies to address VH. TIPS is more commonly utilized in North America and Europe, where portal decompression with or without adjunctive embolization of varices has been a mainstay of endovascular strategy. Conversely, transvenous obliteration evolved in Asia as a direct treatment of VH by obliterating GEVs (particularly GVs) via sclerosis. These approaches were previously viewed as in conflict with one another as obliteration closes GVs but aggravates portal hypertension, whereas TIPS is designed to reduce portal hypertension. Increasingly, however, TIPS and transvenous obliteration are viewed as complimentary procedures that can be combined to reduce bleeding risk and ameliorate sequelae of portal hypertension. Performed together, TIPS and transvenous obliteration result in the elimination of high flow GVs that are at risk for life threatening hemorrhage, with replacement by a man-made endovascular created portosystemic shunt that is not at risk for rupture as well as reduction the risk for post-obliteration EV aggravation, ascites formation, or development of ectopic varices.

Yet, despite a strong mechanistic basis for their combination, there are few studies investigating the effectiveness of combined TIPS plus transvenous obliteration. Thus, the overarching goal of this single center prospective pilot study is to assess the effectiveness and safety of combined TIPS creation plus transvenous obliteration for the treatment of GVs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged = 18 years

• Ability to provide written consent

• Endoscopically proven acute or recurrent VH from GVs, or high risk GVs

Exclusion Criteria:

• Prior indwelling TIPS

• Prior endovascular obliteration procedure

• Elevated heart pressures (left or right)

• Heart failure or severe valvular insufficiency

• Severe pulmonary hypertension

• Rapidly progressive liver failure

• Severe or uncontrolled hepatic encephalopathy

• Uncontrolled systemic infection or sepsis

• Unrelieved biliary obstruction

• Polycystic liver disease

• Extensive primary or metastatic hepatic malignancy

• Severe uncontrolled coagulopathy

• Pregnancy

Related Conditions & MeSH terms

• Bleeding Gastric
• Brain Diseases
• Cirrhosis, Liver
• Encephalopathy
• Esophageal and Gastric Varices
• Fibrosis
• Hypertension
• Hypertension, Portal
• Liver Cirrhosis
• Varicose Veins

Intervention

Device:
• TIPS-obliteration
Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).

Locations

Country	Name	City	State
United States	University of Illinois at Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Chicago

Country where clinical trial is conducted

United States, 

References & Publications (2)

Gaba RC. Retrograde-Antegrade Accelerated Trap Obliteration: A Modified Approach to Transvenous Eradication of Gastric Varices. J Vasc Interv Radiol. 2017 Feb;28(2):291-294. doi: 10.1016/j.jvir.2016.10.004. — View Citation

Saad WE, Wagner CC, Lippert A, Al-Osaimi A, Davies MG, Matsumoto AH, Angle JF, Caldwell S. Protective value of TIPS against the development of hydrothorax/ascites and upper gastrointestinal bleeding after balloon-occluded retrograde transvenous obliterati — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Endoscopic gastric varices eradication rate	Effectiveness outcome	6-months
Primary	Endoscopic esophageal varices aggravation/resolution rate	Effectiveness outcome	6-months
Primary	Imaging gastric variceseradication rate	Effectiveness outcome	1-year
Primary	Gastric varices rebleeding rate	Effectiveness outcome	1-year
Primary	Ascites incidence/improvement rate	Effectiveness outcome	1-year
Secondary	TIPS + transvenous obliteration combined technical success rate	Effectiveness outcome	2-weeks
Secondary	TIPS + transvenous obliteration combined hemodynamic success rate	Effectiveness outcome	2-weeks
Secondary	Procedure related adverse event rate	Safety outcome	30-days
Secondary	Hepatic encephalopathy rate	Safety outcome	1-year
Secondary	Post-TIPS liver failure incidence and degree	Safety outcome	1-year
Secondary	Transplant free survival	Effectiveness outcome	1-year